Farletuzumab: Completed Phase III enrollment

Eisai's Morphotek Inc. subsidiary completed enrollment of 1,080 patients in the double-blind, international Phase III FAR-131 trial comparing 1.25 and 2.5 mg/kg IV farletuzumab weekly in combination ...